Take the Guesswork out of your Recovery.
In remission, information gaps can occur. Oncotrace offers high certainty of primary tumour in a diagnosed patient to help in recovery.
What is OncoTrace?
What it Does: In the early stages of cancer diagnosis, in addition to providing current circulating tumour cell (CTC) values, it can also detect cancer stem cell (CSC) markers to analysze the metastatic spread of these cells.
What it Means: Allows you to stay informed about your risk and take proactive lifestyle changes.
Who's it For: Cancer patients.
How Does it Work?
We Track Dangerous Survivor Cells.
Standard PET/CT scans: Dead DNA fragments only show what the treatment killed. Meanwhile, a tumour can grow to 5mm (millions of cells) before it becomes visible on a scan.
OncoTrace: Instead of tracking killed DNA fragments, we use Live Stem Cells to track what survived. We search for Cancer Stem Cells - the "Mother Cells" responsible for relapse - while they are still microscopic to formulate plans to destroy them.
Immunophenotyping
Through immunophenotyping, it unravels vital information on the cancer's nature, probability of metastatic spread, and likelihood of being chemo resistant.
By analysing cancer behavior at the molecular level, doctors and patients can monitor tumor marker activity related to metastasis, proliferation, drug resistance and metastatic spread.
What Are the Test Components?
1. CTC Count
This test identifies and measures the circulating tumor cells (CTC) count in the blood. The test helps establish a baseline count before treatment.A rise in CTC indicates the treatment is not working, while a decline means the treatment is effective.
2. Phenotype Markers
Oncotrace also reveals phenotype markers that indicate the tissue origin of tumor cells. Particularly beneficial for patients with multiple primary tumors, these markers aid in diagnosis, staging, prognosis, treatment response monitoring, and recurrence evaluation.
3. Stemness Markers
The test also identifies stemness markers associated with cancer behavior and activity in the bloodstream. Even with low CTC counts, active stemness markers mean the cancer is still active. Active stemness markers indicate potential proliferation, risk of metastasis, or possibility of recurrence across early-late stages.
Frequently Asked Questions
What types of tests does RGCC offer?
<FAQ>
Q2
A2
Q3
A3
Q4
A4
